Vesalio announces it has recently raised US$5 million in funding. The capital will support the continued global expansion of the NeVa Neurothrombectomy System, finance key clinical studies and launch new product introductions.
This announcement follows the company’s report regarding its expansion of international distributor network and Stroke Congress Exhibition presence, claiming that it now has market coverage in 39 countries for the NeVa Neuro-thrombectomy system.
“We are very pleased to secure the additional capital funding. We are in the process of initiating several prospective clinical studies for regulatory clearance requirements. In addition to the key studies, we will continue to expand our product offering and geographic sales coverage,” remarked Steve Rybka, CEO of Vesalio.
Founded in 2013, Vesalio is a privately held medical device company focused on advancing technology needed to improve outcomes in stroke treatment. The Company’s proprietary NeVa platform was designed to achieve repeatable and superior clinical outcomes by providing physicians “first pass” success in effectively capturing and retaining a neurovascular clot inside the device.